CAR-T Cell Therapy for Multiple Myeloma - Michaela Liedtke, MD | MCRT Webcast Apr 24, 2021
The Myeloma Crowd brings information from the experts to the patients! Learn more at https://www.myelomacrowd.org/
HealthTree helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/
Видео CAR-T Cell Therapy for Multiple Myeloma - Michaela Liedtke, MD | MCRT Webcast Apr 24, 2021 канала Myeloma Crowd TV by HealthTree
HealthTree helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/
Видео CAR-T Cell Therapy for Multiple Myeloma - Michaela Liedtke, MD | MCRT Webcast Apr 24, 2021 канала Myeloma Crowd TV by HealthTree
Показать
Комментарии отсутствуют
Информация о видео
12 мая 2021 г. 0:57:03
00:23:54
Другие видео канала
What is CAR T Cell Therapy?
Myeloma for Patients Who Are Just Getting Started
BCMA and Treatment Strategies - Krina Patel, MD, MSc | MCRT Webcast Apr 10, 2021
Applications in biomarker discovery and CAR T therapy using high-plex RNA
A "living drug" that could change the way we treat cancer | Carl June
CAR T at UCLA: Driving the Progress of Engineered Cell Therapy | Sarah Larson, MD | UCLAMDChat
Update on CAR T Cell Therapy for Diffuse Large B-Cell Lymphoma Webinar – May 27, 2020
2019 Multiple Myeloma Symposium | Diagnosis, Prognosis & Risk
Webinar: "Anti-HER2 CAR-Macrophages Clinical Study"
CAR-T Therapy for Multiple Myeloma | MCRT Webcast Jan 30, 2021
Multiple Myeloma: Stem Cell Transplant and Beyond
Best Multiple Myeloma Therapies for Elderly Patients
Multiple Myeloma Stem Cell Transplant
What Is BCMA
Understanding MGUS and SMM Progression - Irene Ghobrial, MD | MCRT Webcast September 26 (2/3)
Updates in CAR T Cell Therapies
Improving CAR-T Cell Therapies (Immunotherapy Documentary Part III)
New treatment horizon : Chimeric Antigen Receptor CAR T Cell Therapy
Multiple Myeloma - signs and symptoms, pathophysiology, treatment
Multiple Myeloma – Is It Now a Curable Disease?